Vita, Emanuele
 Distribuzione geografica
Continente #
NA - Nord America 1.501
AS - Asia 908
EU - Europa 642
SA - Sud America 220
Continente sconosciuto - Info sul continente non disponibili 45
AF - Africa 27
OC - Oceania 3
Totale 3.346
Nazione #
US - Stati Uniti d'America 1.448
SG - Singapore 405
IT - Italia 213
CN - Cina 188
BR - Brasile 178
SE - Svezia 104
VN - Vietnam 100
DE - Germania 67
FR - Francia 56
IN - India 49
GB - Regno Unito 41
FI - Finlandia 28
CA - Canada 25
AR - Argentina 23
BD - Bangladesh 22
HK - Hong Kong 22
JP - Giappone 22
NL - Olanda 22
ID - Indonesia 21
IE - Irlanda 18
KR - Corea 18
MX - Messico 17
RU - Federazione Russa 15
TR - Turchia 14
AT - Austria 13
IQ - Iraq 12
PL - Polonia 12
CZ - Repubblica Ceca 10
ES - Italia 9
ZA - Sudafrica 8
EC - Ecuador 7
UA - Ucraina 7
LT - Lituania 6
CO - Colombia 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
CI - Costa d'Avorio 4
JO - Giordania 4
TN - Tunisia 4
AL - Albania 3
BG - Bulgaria 3
IR - Iran 3
UZ - Uzbekistan 3
AU - Australia 2
AZ - Azerbaigian 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
MA - Marocco 2
NI - Nicaragua 2
NP - Nepal 2
PH - Filippine 2
RO - Romania 2
UY - Uruguay 2
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
CL - Cile 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GI - Gibilterra 1
HU - Ungheria 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
ML - Mali 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
PR - Porto Rico 1
PT - Portogallo 1
PY - Paraguay 1
QA - Qatar 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
VE - Venezuela 1
Totale 3.302
Città #
Singapore 251
Ashburn 144
San Jose 111
Rome 71
New York 57
Chandler 56
Los Angeles 40
Hefei 39
Ho Chi Minh City 39
Hyderabad 35
The Dalles 32
Beijing 27
Council Bluffs 27
St Louis 25
Milan 24
Hanoi 23
Tokyo 22
Dallas 20
Frankfurt am Main 20
Hong Kong 20
Lauterbourg 19
São Paulo 19
Atlanta 18
Boardman 18
Dublin 18
Santa Clara 18
Jakarta 17
Munich 17
Cattolica 16
Seoul 16
Buffalo 15
Helsinki 13
Chicago 11
Kent 11
Orem 11
Brno 9
Brooklyn 9
Paris 9
Turku 9
Boston 8
Denver 8
Düsseldorf 8
Montreal 8
Moscow 8
Vienna 8
Warsaw 8
Princeton 7
San Mateo 7
Stockholm 7
Amsterdam 6
Bexley 6
Bremen 6
Da Nang 6
Des Moines 6
Lappeenranta 6
Phoenix 6
Poplar 6
Johannesburg 5
London 5
Marseille 5
Mexico City 5
Quito 5
Toronto 5
Abidjan 4
Amman 4
Baghdad 4
Brussels 4
Charlotte 4
Falkenstein 4
Goiânia 4
Guangzhou 4
Haiphong 4
Houston 4
Madrid 4
Miami 4
Middlesbrough 4
North Bergen 4
Nuremberg 4
Odesa 4
Orangeburg 4
Portsmouth 4
Riyadh 4
San Francisco 4
Seattle 4
Wroclaw 4
Ankara 3
Bắc Ninh 3
Campinas 3
Chennai 3
Cuiabá 3
Erbil 3
Fairfield 3
Huzhou 3
Manaus 3
Manchester 3
Memphis 3
Naples 3
New Orleans 3
Orlando 3
Ottawa 3
Totale 1.644
Nome #
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 334
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer 317
Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 261
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study 174
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study 167
From palliation to cure: PIPAC for peritoneal malignancies 154
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 149
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 145
Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives 140
Prognostic factors and long-term survival in locally advanced nsclc with pathological complete response after surgical resection following neoadjuvant therapy 137
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors 136
Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics 123
Comparative Analysis of Comprehensive Genomic Profile in Thymomas and Recurrent Thymomas Reveals Potentially Actionable Mutations for Target Therapies 121
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer 118
Role of Peripheral Blood Markers for Detecting Response and Predicting Prognosis in Patients with Non-small-cell Lung Cancer Undergoing Neoadjuvant Therapy and Surgery 118
Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review 114
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 112
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) 110
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis 107
Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis 104
Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma 84
Surgery after induction chemo or immunotherapy for locally advanced NSCLC 82
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib 23
Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practice 12
Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature review 4
Totale 3.346
Categoria #
all - tutte 11.847
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.847


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202252 0 0 1 14 1 1 0 8 2 2 8 15
2022/2023157 21 20 13 27 9 23 11 8 18 0 2 5
2023/2024203 3 35 9 10 8 18 26 9 2 21 21 41
2024/2025679 23 6 41 34 42 30 32 20 85 109 146 111
2025/20261.821 180 78 110 259 295 69 215 83 114 106 94 218
2026/2027391 71 320 0 0 0 0 0 0 0 0 0 0
Totale 3.346